“Effect of combined administration of new type 2 diabetes mellitus was demonstrated in animal experiments”
“A synergistic effect from diabetes control to kidney and pancreatic protection”
diabetes. Getty Images Bank
When ‘SGLT2 inhibitor’ and ‘DPP4 inhibitor’, a new drug for type 2 diabetes (adult diabetes), are administered together, it shows a synergistic effect in the treatment of diabetes caused by the immunosuppressant ‘tacrolimus’ taken to prevent rejection following kidney transplantation. came out as a result of the study.
The results of this study suggest a new treatment direction for diabetes that occurs following kidney transplantation, and are expected to provide hope for the treatment of diabetes in transplant patients in the future.
The research team led by Professor Yang Cheol-woo (corresponding author), Professor Ko Eun-jeong (first author), and Research Professor Lim Seon-woo of the Institute of Clinical Medicine, Seoul St. Mary’s Hospital, Catholic University of Korea It was confirmed on the 26th that it has confirmed that it has protective effects on pancreas and kidneys, and that the combined treatment is superior in diabetes control than when administered alone.
Diabetes mellitus following kidney transplantation shortens the lifespan of the transplanted kidney and increases cardiovascular complications, which can even threaten the life of the patient. There are various factors that cause diabetes following transplantation.
SGLT2 inhibitor, a new diabetes drug developed recently, suppresses the reabsorption of glucose absorbed by the renal tubule and excretes glucose in the urine, thereby lowering blood sugar. It lowers blood sugar by stimulating the secretion of insulin.
These drugs are in the spotlight as a treatment for type 2 diabetes due to their mechanisms differentiated from existing diabetes drugs.
Professor Yang said, “Until now, there was no clear treatment manual for patients who developed diabetes following transplantation, so it was applied to the treatment for type 2 diabetes patients. Proving that, we have presented a new standard for diabetes treatment for organ transplant patients.”
He added, “The combined administration of a SGTL2 inhibitor and a DPP4 inhibitor not only lowers blood sugar but also has a synergistic effect to prevent damage to the kidney and pancreas, so it is expected to be effective in preventing cardiovascular complications in kidney transplant patients.”
The results of this study were published in the ‘American Journal of Transplantation’, the official academic journal of the American Transplantation Society, on the 16th of last month.
